E
Bio-Path Holdings, Inc. BPTH
$0.14 -$0.005-3.45% OTC PK
Recommendation
Prev Close
$0.145
Volume
10,455
Avg Vol (90D)
1,658,879
Market Cap
$1.20M
Dividend & Yield
--
52-Week Range
$0.12 - $4.55
P/E (TTM)
--
EPS (TTM)
-$7.38
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Bio-Path Holdings Reports Full Year 2024 Financial Results
3/28/2025 - Globe Newswire
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
3/18/2025 - Globe Newswire
Bio-Path (NASDAQ:BPTH) Files 8-K - Discloses Amendment to Rights AgreementHOUSTON, TEXAS-(BusinessWire - February 25, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company focused on developing targeted RNAi therapeutics for the tr
2/21/2025 - Ticker Report
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc
2/15/2025 - GuruFocus
Bio-Path Holdings Expands Global Patent Portfolio
2/13/2025 - GuruFocus
Bio-Path Holdings Expands Global Patent Portfolio
2/13/2025 - Globe Newswire
Bio-Path Holdings Provides Key Clinical Updates
2/13/2025 - GuruFocus
Bio-Path Holdings Provides Key Clinical Updates
2/13/2025 - Globe Newswire
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of ...
2/12/2025 - GuruFocus
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
2/12/2025 - Globe Newswire
Bio-Path Holdings Advances Clinical Pipeline for 2025
1/10/2025 - TipRanks Financial Blog
Bio-Path Holdings Provides 2025 Clinical and Operational Update
1/10/2025 - GuruFocus
Bio-Path Holdings Provides 2025 Clinical and Operational Update
1/10/2025 - Globe Newswire
Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Preclinical Study Results
12/19/2024 - GuruFocus
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity ...
12/19/2024 - GuruFocus
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
12/19/2024 - Globe Newswire
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes
12/13/2024 - TipRanks Financial Blog
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
12/13/2024 - Newsfile Corp. - News Releases
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for ...
12/11/2024 - GuruFocus
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
12/11/2024 - Globe Newswire
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...
11/21/2024 - GuruFocus
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
11/20/2024 - Zacks Investment Research
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
11/20/2024 - Zacks Investment Research
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2024 Earnings Call Transcript
11/16/2024 - Insider Monkey
Bio-Path Holdings Expands DNAbilize Technology Applications
11/16/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$11.94M
EBIT (TTM)
-$11.99M
Net Income (TTM)
-$9.89M
Balance Sheet
Total Assets (Q)
$3.88M
Total Debt (Q)
$83.00K
Total Liabilities (Q)
$3.73M
Book Value Per Share (Q)
$0.0267
Cash Flow
Cash from Operations (TTM)
-$10.58M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$10.70M
Net Change in Cash (TTM)
$121.00K
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.47
7-Day Total Return
-6.67%
30-Day Total Return
-15.46%
60-Day Total Return
-82.84%
90-Day Total Return
-78.83%
Year to Date Total Return
-87.83%
1-Year Total Return
-94.78%
2-Year Total Return
-99.43%
3-Year Total Return
-99.75%
5-Year Total Return
-99.87%
52-week Low
Apr 17, 2025 - $0.12
52-week High
Jun 03, 2024 - $4.55
Valuation
Market Cap
$1.20M - Nano Cap
Enterprise Value
$114.66K
Price/Sales (TTM)
--
Price/Book (Q)
5.43
Dividends and Shares
Shares Outstanding
4.32M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biopathholdings.com
Phone Number
832 742 1357
Address
4710 Bellaire Boulevard
Bellaire, TX 77401
Country
United States
Year Founded
2007
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology... more
OTC PK 04/28/2025 2:53PM Eastern Quotes delayed